Liver metastases are secondary hepatic tumors that arise when malignant cells from a primary tumor elsewhere in the body disseminate to the liver. They are considerably more common than primary liver malignancies and account for the majority of malignant hepatic lesions. Owing to the liver's central role in the circulation, particularly the portal venous system, it is a preferential site for metastatic spread.
Depending on the primary malignancy and the extent of metastatic disease, treatment may be pursued with curative intent or may achieve durable long-term disease control, particularly in an oligometastatic setting characterized by a limited number of confined metastatic lesions.
In colorectal cancer, liver metastases are considered potentially curable when complete surgical resection or complete local ablation is feasible. Radiosurgery may also be used for consolidation of residual tumor following resection.
Liver metastases frequently remain asymptomatic for a prolonged period and are often detected on imaging performed as part of oncological follow-up. Symptoms typically develop with increasing tumor burden or impairment of hepatic function.
Liver metastases from neuroendocrine tumors (NETs) may cause carcinoid syndrome as a consequence of uncontrolled hormone secretion, with episodic cutaneous flushing, watery diarrhea, bronchospasm, and cardiac involvement (Hedinger syndrome / carcinoid heart disease).
Accurate diagnosis and characterization of liver metastases form the basis of every treatment strategy. The principal objectives are to determine the number, size, and anatomical location of the metastatic lesions and to assess their relationship to hepatic vessels and the biliary system.
The treatment of liver metastases is multimodal. The primary tumor, number and location of the metastases, hepatic function, and the patient's overall clinical condition are decisive factors. Treatment decisions are made on an interdisciplinary basis within a multidisciplinary tumor board.
Stereotactic body radiotherapy (SBRT) has become established as a highly effective and safe treatment modality for liver metastases. Using CyberKnife, very high radiation doses can be delivered to each individual metastasis with millimeter-level precision while maximizing protection of uninvolved hepatic parenchyma, the biliary tract, and adjacent organs.
A major advantage of the CyberKnife system in the treatment of liver tumors is real-time respiratory motion compensation. The liver may move by as much as 2-3 cm during respiration. CyberKnife continuously tracks this motion and dynamically maintains precise beam alignment with the metastasis without interrupting treatment, allowing the patient to breathe normally throughout the procedure. Current studies of SBRT for liver metastases report local control rates of approximately 70-90% at 2 years, comparable with ablation or surgical resection in appropriately selected patients. Treatment is delivered in 3-6 sessions on an outpatient basis and does not require general anesthesia. Multiple metastases can also be treated within a single treatment series.
At the European Radiosurgery Center Munich, we have been treating patients with liver metastases from a wide range of primary malignancies for more than 20 years. Each treatment plan is individualized in close coordination with the patient's treating oncology and surgical teams.
Liver metastases develop when malignant cells from another primary tumor - for example colorectal, breast, or lung cancer - disseminate to the liver.
A primary liver tumor, such as hepatocellular carcinoma (HCC), arises from the liver cells themselves and frequently develops in the setting of liver cirrhosis. These two disease entities differ fundamentally in terms of treatment, prognosis, and therapeutic planning.
Particularly in colorectal cancer, isolated liver metastases can be durably controlled or cured in a proportion of patients through complete surgical resection, local ablation, or radiosurgery. In selected patients with other primary malignancies, an oligometastatic disease state may likewise be approached with curative intent.
In many cases, yes. However, an appropriate interval from chemotherapy is generally advisable in order to minimize treatment-related toxicity. The exact timing is determined individually in coordination with the treating oncology team. Targeted therapies and immunotherapies are often continued concomitantly.
Yes. CyberKnife® treatment may also be used for recurrent disease following surgery or ablation and can be effectively combined with systemic therapies. Previous hepatic irradiation may limit retreatment options; however, depending on the previously delivered dose and the anatomical location, repeat irradiation may still be considered in selected cases.
In principle, SBRT can be used in an oligometastatic setting, typically involving 1-5 metastases. When several lesions are present, they may be irradiated within one or multiple treatment series. The treatment decision depends on the total metastatic tumor volume, the volume of remaining healthy liver parenchyma, and overall hepatic function.
As treatment options have become increasingly complex, the choice of therapy should always take the patient's individual circumstances and personal situation into account. It is important to us that patients, their families, and those close to them who provide support fully understand the relevant aspects of the disease and the available treatment options. Together with our medical partners, we accompany patients throughout this process and ensure that they feel comprehensively cared for at the ERCM from the very beginning.
For treatment enquiries, please use the contact form. You may also contact us by telephone during our opening hours or via our social media channels. Each enquiry is reviewed individually and processed promptly.